Clicky

Genmab(0MGB) News

Date Title
Jul 1 Genmab Announces Changes to its Executive Committee
Jun 30 Completion of Share Buy-back Program
Jun 17 Capital Increase in Genmab as a Result of Employee Warrant Exercise
Jun 15 Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)
May 27 Genmab to Participate in a Fireside Chat at the 46th Goldman Sachs Annual Global Healthcare Conference
May 22 Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
May 21 Genmab to Participate in a Fireside Chat at the 2025 Jefferies Global Health Care Conference
Apr 15 Genmab (CPSE:GMAB) Reports US$3 Billion DARZALEX Sales For Q1 2025
Apr 15 Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025
Apr 14 Transactions in Connection with Share Buy-back Program
Apr 10 Genmab A/S Share Capital Reduction
Mar 31 TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer
Mar 31 Transactions in connection with share buy-back program
Mar 27 TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy
Mar 25 Genmab Announces Initiation of Share Buy-Back Program
Mar 12 Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Mar 12 Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab
Mar 12 Passing of Genmab A/S’ Annual General Meeting
Mar 11 Genmab says J&J not exercising option on HexaBody-CD38
Mar 10 Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38